



KABRA DRUGS LIMITED

CIN-L02423MP1989PLC005438

To
Department of Corporate Services,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001

29 October 2022

Sir/ Madam,

**Subject: Reconciliation of Share Capital Audit for Q.E. 30.09.2022- Submission of – Reg.
Reference: Kabra Drugs Limited (524322).**

With reference to above, we hereby enclose the Reconciliation of Share Capital Audit for quarter ended 30th September 2022 from Practicing Company Secretary.

This is for your information and record.

Thanking you,

Yours faithfully

For, KABRA DRUGS LIMITED



DIRECTOR / AUTHORISED SIGNATORY



28.10.2022

To,

BSE LIMITED

Dear Sir,

Sub: Reconciliation of Share Capital Audit Report for the quarter ended 30th September 2022.

We are enclosing herewith the Reconciliation of Share Capital Audit report of M/s. KABRA DRUGS LIMITED for the quarter ended 30th September 2022.

Thanking You,

Yours faithfully,

Narasimhan Srividhya
Practicing Company Secretary



RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

1 For Quarter Ended	30 th September 2022
2 ISIN:	INE23K01017
3 Face Value:	Rs. 10/- per share
4 Name of the Company	KABRA DRUGS LIMITED
5 Registered Office Address	270 Shastri Market Indore MP 452007 IN
6 Correspondence Address	Same as above
7 Telephone & Fax Nos.	Tel.No. 0731-2971305/6501305
8 Email address	kabradrugs@rediffmail.com
9 Names of the Stock Exchanges where the company's securities are listed	Bombay Stock Exchange Ltd.

	Number of shares	% of Total Issued Capital
10 Issued Capital	43,88,600	100%
11 Listed Capital (Exchange-wise) (as per company's records) Bombay Stock Exchange Ltd:		
12 Held in dematerialized form in CDSL	11,86,440	27.04
13 Held in dematerialized form in NSDL	17,40,659	39.66
14 Physical	14,61,501	33.30
15 Total No. of shares (12+ 13+ 14)	43,88,600	100.00%
16 Reasons for difference if any, between (10&11), (10&15),	N.A.	

- 17 Certifying the details of changes in share capital during the quarter under consideration as per Table below:

Particulars	No. of Shares	Applied /Not Applied for listing	Listed on Stock Exchanges (specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (specify Names)
--	--	--	Nil	--	--	--

***Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).

- 18 Register of Members is Updated (Yes/No)

YES
Not Applicable

If not, updated up to which date

- 19 Reference of Previous Quarter with regards to excess dematerialized shares, if any

Nil

- 20 Has the company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?

Not Applicable

- 21 Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of Shares	Reasons for delay
Confirmed after 21 Days	Nil	Nil	NA
Pending for more than 21 days	Nil	Nil	NA

22 Name, Telephone and Fax No. of the Compliance officer of the Co.

Ms. Monika Nishant
Membership Number:58835
Company Secretary
Ph: 022-28523437

23 Name, Address, Tel .& Fax No., Regn. No of the Auditor

NarasimhanSrividhya
Company Secretaries in Practice-CP.No.14058
No.161-1Jayalakshmi Apartment, Lake view
Road, West Mamabalam,Chennai - 33
e-mail id-srividhya0806@gmail.com
Phone No.-9791712781

24 Appointment of common agency for share registry work
If yes (name & address)

M/s. Skyline Financial Services Pvt. Ltd.
A/505, Dattani Plaza, Andheri Kurla Road,
Safeed Pool, Mumbai- 400072.

25 Any other detail that the auditor may like to provide. (e.g.BIFR Company, delisting from SE, company changed its name etc.)

-----Nil-----

Date: 28.10.2022
Place: Chennai

N.S. Srividhya

Narasimhan Srividhya
Practicing Company Secretary
CP No.14058
UDIN:A034428D001392576
Peer Review Certificate No:829/2020
Unique Code:P2004TN081200

NARASIMHAN SRIVIDHYA
Company Secretary In Practice
Mem. No : 34428
Cop : 14058